New combo therapy trial aims to control advanced blood cancer
NCT ID NCT06984146
Summary
This study is testing whether a lower, flat dose of the immunotherapy drug nivolumab, when combined with standard chemotherapy, is effective and safe for adults newly diagnosed with advanced Hodgkin lymphoma. The goal is to control the disease and prevent it from progressing. Researchers will monitor 54 participants over six treatment cycles to see how well the combination works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
P. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation
RECRUITINGMoscow, Russia
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.